SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Schrodinger, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.12+0.52 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Schrodinger, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Software | $35.47M | $35.56M | $69.28M | $40.86M | $40.54M | $48.82M | $79.66M | $31.88M | $35.40M | $33.42M | $68.66M | $28.90M | 60.2% | -12.5% |
| Drug Discovery | $23.42M | $23.03M | $17.95M | $13.47M | $14.22M | $10.74M | $8.66M | $3.41M | $11.93M | $3.18M | $5.47M | $13.67M | 39.8% | +64.8% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Software products and services | $32.54M | $35.56M | $69.28M | $40.86M | $36.03M | $44.97M | $79.66M | $31.88M | $35.40M | $33.42M | $68.66M | $28.90M | 55.3% | -9.7% |
| Drug discovery | $22.99M | $22.88M | $17.95M | $13.47M | $13.94M | $10.24M | $8.66M | $3.41M | $11.93M | $3.18M | $5.47M | $13.67M | 39.0% | +64.9% |
| Hosted software | $15.15M | $12.08M | $11.54M | $11.59M | $11.13M | $10.87M | $11.18M | $8.81M | $8.09M | $7.18M | $6.02M | $5.46M | 25.7% | +36.1% |
| On-premise software | $9.30M | $14.18M | $44.35M | $15.93M | $15.74M | $25.42M | $55.39M | $12.25M | $18.76M | $17.62M | $53.95M | $13.81M | 15.8% | -40.9% |
| Software maintenance | $4.88M | $6.66M | $6.89M | $6.83M | $6.78M | $6.80M | $5.89M | $5.66M | $5.84M | $5.90M | $5.69M | $5.75M | 8.3% | -28.0% |
| Contribution | $3.36M | $148.00K | – | – | $4.79M | $4.34M | – | $3.12M | $0 | $0 | – | $1.80M | 5.7% | -29.8% |
| Professional services | $3.22M | $2.64M | $3.80M | $1.59M | $2.38M | $1.88M | $2.32M | $2.04M | $2.72M | $2.73M | $3.01M | $2.08M | 5.5% | +35.1% |
| Software contribution | $2.92M | $0 | – | – | $4.51M | $3.84M | – | – | – | – | – | – | 5.0% | -35.3% |
| Drug discovery contribution | $438.00K | $148.00K | – | – | $275.00K | $499.00K | – | – | – | – | – | – | 0.7% | +59.3% |
| Revenue from contracts with customers | – | – | – | $35.93M | $36.03M | $44.97M | – | $28.76M | $35.40M | $33.42M | – | $27.10M | – | – |
| Software contribution | – | – | $17.58M | $13.01M | $13.94M | $10.24M | $8.13M | $2.81M | $11.51M | $2.69M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $37.53M | $31.41M | $57.92M | $31.33M | $34.05M | $29.66M | $36.25M | $24.62M | $30.70M | $23.30M | $54.53M | $33.13M | 63.7% | +10.2% |
| APAC | $14.38M | $20.17M | $22.80M | $15.72M | $13.56M | $23.08M | $45.50M | $5.15M | $8.71M | $7.20M | $13.72M | $3.76M | 24.4% | +6.0% |
| EMEA | $6.70M | $6.67M | $6.38M | $6.76M | $6.97M | $6.07M | $6.31M | $5.28M | $7.81M | $5.50M | $5.69M | $5.57M | 11.4% | -3.9% |
| Rest of World | $285.00K | $333.00K | $141.00K | $515.00K | $175.00K | $731.00K | $250.00K | $243.00K | $121.00K | $604.00K | $191.00K | $117.00K | 0.5% | +62.9% |
From the segment and revenue-disaggregation notes of Schrodinger's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.